Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“CRITICS-II: multicenter Ph2 RCT in resectable gastric cancer showing preop chemo (DOC) + CRT improved 1-yr EFS and pCR (20%) v CRT or chemo alone. But with D-FLOT now SOC, the questions are:
- Could adding pre-op chemoRT to D-FLOT further improve pCR, enabling an organ preservation option?
- Even with planned surgery, is there a high-risk subset (bulky T4, threatened margins) in whom local intensification could benefit?
- Feasibility: Can chemoRT be integrated without compromising the completion of modern intensified systemic therapies?
More thoughts to come. Nice to see a positive RT trial in gastric ca, albeit with limitations.”
More posts featuring Nina Niu Sanford.
